Listen

News

Sawai Receives Approvals for 4 Generic Drugs with 13 Strengths

Aug. 17. 2020

Osaka, Japan - August 17, 2020 - Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for 4 generic drugs with 13 strengths. The 2 compounds marked with an asterisk below are approved for the first time as generics.

The list of approved products

1. Pregabalin OD Tablets, Capsules

Generic name Pregabalin*
Strengths OD Tablets, Capsules: 25 mg, 75 mg, 150 mg
Brand products Lyrica® OD Tablets 25 mg, 75 mg, 150 mg,
Lyrica® Capsules 25 mg, 75 mg, 150 mg

2. Rivastigmine Tapes

Generic name Rivastigmine*
Strengths 4.5 mg, 9 mg, 13.5 mg, 18 mg 
Brand products EXELON® PATCH 4.5 mg, 9 mg, 13.5 mg, 18 mg,
RIVASTACH® Patches 4.5 mg, 9 mg, 13.5 mg, 18 mg

3. Bortezomib for Injection

Generic name Bortezomib
Strengths 3 mg
Brand products VELCADE® Injection 3 mg

4. Famotidine Intravenous Injection

Generic name Famotidine
Strengths 10 mg, 20 mg
Brand products Gaster® Injection 10 mg, 20 mg

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.